MHE Week in Review – AMCP Annual 2025 Review

ProAct Chief Operating Offier Deborah Dempsey says plan sponsors still lack the data and visibility to know whether they were shorted on a 340B claim.

AACR Cancer Progress Report 2026 highlights a 35% U.S. cancer death decline, new FDA advances, persistent disparities, and urgent calls for stronger NIH/NCI funding.

OrionRx's Don Anderson, Pharm.D., says a GLP-1 access model built around mandatory wellness coaching resulted in a six-point drop in body mass index and improved mental health.

Yellow eyelid Xanthelasma signals hidden high cholesterol and cardiovascular disease risk, tripling heart attack and stroke odds; Negin Yavari, M.D., and her team urge screening.

Maladaptive coping at baseline raised relapse and symptom risk over 12 months in first episode psychosis, King's College London researchers found.

Navitus launched three modular options that let plan sponsors manage diabetes, weight, and lifestyle therapy access, cost, and outcomes with guaranteed ROI.

ProAct's Deborah Dempsey, Pharm.D., MBA, RPh, explains how 340B discounts to healthcare entities are in conflict with rebates that manufacturers pay to health plan sponsors.

Optum Rx's Anne Mall, M.H.A., says her company's AI is surfacing clinical details buried in providers' chart notes so clinicians can decide on therapy faster.